Tamtam Try Tamtam free
Elekta logo

Elekta account plan

Developing precision radiation therapy

At a glance

Elekta is a Stockholm-listed precision radiotherapy group with SEK 16,718 M net sales in FY 2025/26 and about 7,500 devices installed in 130+ countries.

Elekta, based in Stockholm and listed on Nasdaq Stockholm, develops, makes and sells hardware, software and services for precision radiotherapy, radiosurgery and brachytherapy: linear accelerators (Harmony, Evo, Unity MR-Linac), Leksell Gamma Knife, Flexitron afterloaders and the Elekta ONE oncology software. Its installed base is about 7,500 devices and software solutions at 2,500 clinics in more than 130 countries. In FY 2025/26 (May 2025-April 2026) net sales were SEK 16,718 M, with an adjusted EBIT margin of 12.3% but a net income of SEK -517 M after impairments and restructuring charges; Solutions were 56% and Service 44% of sales. It had 4,102 employees at year-end, and founder Laurent Leksell chairs the board, holding 30.23% of votes. President and CEO is Jakob Just-Bomholt.

Business units

Strategic priorities

Three-phase turnaround
Reset and stabilize (completed), improve profitability (FY 2026/27), then innovation-driven growth; the new regional P&L operating model cut annualized costs by more than SEK 500 million and headcount to below 4,000.
Win in the U.S. and expand in China
The U.S. is only 20% of revenue; Elekta targets mid-to-high single-digit revenue CAGR in the Americas over three years, and in China aims to keep leadership while deepening localization.
Focused innovation in adaptive radiotherapy
R&D at about 10% of revenue on fewer core products, with a launch wave within 12 months: next-generation Iris imaging, real-time CT motion management, an integrated console, a 6D table and Unity Pro 30-minute MR-Linac slots.
Continuous COGS reduction and pricing
Dual sourcing, cost-efficient suppliers, AI tools for field service engineers and simpler installation, plus a new pricing framework with floor ASPs and an expected price uplift of 2-3%.
FY 2028/29 mid-term targets
Mid-single-digit sales CAGR in fixed currency, a 14-16% adjusted EBIT margin and free cash flow before dividends of about 10% of sales.

Latest results

In Q1 2026/27 (May-July 2026) net sales fell to SEK 3,536 M (3,646), -2% at constant exchange rates: Solutions fell 9% while Services grew 5% with growth in all regions. Profitability jumped, with an adjusted gross margin of 42.6% (37.0) and adjusted EBIT of SEK 395 M, a margin of 11.2% (6.5); a US tariff refund of SEK 53 M added 150 basis points. Net income was SEK 261 M (106) and book-to-bill 1.11, driven by Elekta Evo. The FY 2026/27 outlook was reiterated: net sales +2-4% in constant currency and an adjusted EBIT margin of 12.5-13.5%.

Investments and deals

R&D spend
Gross R&D held at about 10% of revenue; continuous investments were SEK 1,072 M in FY 2025/26, mostly in the linac family and software.
EIB credit facility
A EUR 100 M credit facility with the European Investment Bank for R&D project funding, signed on August 24, 2026, with up to 6 years maturity.
Portfolio clean-up
Impairments of SEK 1,096 M in FY 2025/26, mainly discontinued R&D projects and SEK 235 M of goodwill from the Kaiku wind-down.
Croatia distributor assets
Elekta acquired assets from its distributor in Croatia in June 2025.

Challenges and risks

Growing slower than the market
The CEO puts radiotherapy market growth at roughly 6% and says Elekta is "still not growing with the market"; Q1 2026/27 sales fell 2% at constant currency.
Competition and price pressure
Siemens Healthineers (Varian) is the main competitor and United Imaging competes in China, where volume-based and centralized procurement add price pressure.
Order backlog quality
A backlog review led to SEK 2.2 billion of cancellations and stricter order criteria such as prepayment, site readiness and delivery within three years.
Geopolitics, tariffs and currency
Tariffs, sanctions and Middle East conflicts delayed installations in TIMEA; costs in GBP and CNY against USD revenue create currency exposure.
Cyber and data privacy
The annual report lists data privacy and cyber attacks on healthcare data, including agentic AI, among its risks.

What leadership says

“This year is really about improving the underlying profitability of the company.”

Jakob Just-Bomholt, President and CEO · Q1 2026/27 earnings call (27 August 2026)

“We are still not growing with the market. That is highly unsatisfactory.”

Jakob Just-Bomholt, President and CEO · Q1 2026/27 earnings call (27 August 2026)

“is going to be a lifestyle. It's not a diet.”

Jakob Just-Bomholt, President and CEO · On cost discipline, Capital Markets Day 2026 (17 June 2026)

Where a supplier can help

COGS reduction and sourcing
The continuous COGS reduction battle relies on dual sourcing and cost-efficient suppliers, an opening for component, manufacturing and procurement partners.
Field service productivity
AI tools for field service engineers and simpler installation are part of the COGS programme, and Services grew in every region; service management and AI support tooling fit here.
U.S. commercial execution
Winning in the U.S., where Elekta has only 20% of revenue and Evo orders are growing, calls for sales enablement, market intelligence and customer-facing tools.
Software and interoperability
Focused innovation includes Elekta ONE, a new interoperability API and GPU-accelerated planning, which suits cloud, compute and software engineering partners.
Healthcare data security
Cyber attacks on healthcare data, including agentic AI, are a named risk, supporting security and compliance offers for its connected software.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Elekta?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Elekta

What does Elekta do?

Elekta makes precision radiotherapy equipment, software and services, including linear accelerators, the Unity MR-Linac, Leksell Gamma Knife, brachytherapy afterloaders and the Elekta ONE oncology software.

What is Elekta's revenue?

Net sales were SEK 16,718 M in FY 2025/26 (May 2025-April 2026), +1% at constant exchange rates. Q1 2026/27 net sales were SEK 3,536 M.

How many employees does Elekta have?

Elekta had 4,102 employees at the end of FY 2025/26, and management says headcount is now below 4,000.

What is Elekta's strategy?

A three-phase turnaround built on four Must-Win Battles: Simplify, Empower, Speed; Focused Innovation; Win in the U.S. and expand in China; and continuous COGS reduction, targeting a 14-16% adjusted EBIT margin by FY 2028/29.

Who leads Elekta?

Jakob Just-Bomholt is President and CEO, Klara Eiritz CFO, and founder Laurent Leksell chairs the board.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)